Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis

Archive ouverte

Smeele, Patrick | D’almeida, Sènan | Meiller, Clément | Chéné, Anne-Laure | Liddell, Charly | Cellerin, Laurent | Montagne, François | Deshayes, Sophie | Benziane, Sarah | Copin, Marie-Christine | Hofman, Paul | Le Pimpec-Barthes, Françoise | Porte, Henri | Scherpereel, Arnaud | Grégoire, Marc | Jean, Didier | Blanquart, Christophe

Edité par CCSD ; BioMed Central -

International audience. Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer related to asbestos exposure. The discovery of soluble biomarkers with diagnostic/prognostic and/or therapeutic properties would improve therapeutic care of MPM patients. Currently, soluble biomarkers described present weaknesses preventing their use in clinic. This study aimed at evaluating brain-derived neurotrophic factor (BDNF), we previously identified using transcriptomic approach, in MPM. We observed that high BDNF expression, at the mRNA level in tumors or at the protein level in pleural effusions (PE), was a specific hallmark of MPM samples. This protein presented significant but limited diagnostic properties (area under the curve (AUC) = 0.6972, p < 0.0001). Interestingly, high BDNF gene expression and PE concentration were predictive of shorter MPM patient survival (13.0 vs 8.3 months, p < 0.0001, in PE). Finally, BDNF did not affect MPM cell oncogenic properties but was implicated in PE-induced angiogenesis. In conclusion, BDNF appears to be a new interesting biomarker for MPM and could also be a new therapeutic target regarding its implication in angiogenesis.

Suggestions

Du même auteur

Involvement of the M-CSF/IL-34/CSF- 1R pathway in malignant pleural mesothelioma

Archive ouverte | Blondy, Thibaut | CCSD

International audience. Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer related to asbestos exposure. The tumor microenvironment content, particularly the presence of macrophages, wa...

Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications

Archive ouverte | Blum, Yuna | CCSD

International audience. Malignant pleural mesothelioma (MPM) is recognized as heterogeneous based both on histology and molecular profiling. Histology addresses inter-tumor and intra-tumor heterogeneity in MPM and d...

Genetic alterations of malignant pleural mesothelioma: association to tumor heterogeneity and overall survival Author names

Archive ouverte | Quetel, Lisa | CCSD

International audience. Development of precision medicine for malignant pleural mesothelioma (MPM) requires a deep knowledge of tumor heterogeneity. Histologic and molecular classifications and histo-molecular gradi...

Chargement des enrichissements...